Position of the Transparency Council – Keytruda (pembrolizumab)
At its meeting on 3 February 2025, the Transparency Council adopted position No. 14/2025 on the evaluation of the drug Keytruda (pembrolizumab) within the drug program: B.6. “Treatment of patients with lung cancer (ICD-10: C34) and pleural mesothelioma (ICD-10: C45)” (monotherapy)